Submission of Transcript of H2 & FY2026 Investor Conference Call as per Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shelter Pharma, a 60-year-old Gujarat-based Ayurvedic and herbal healthcare company, reported FY26 revenue of ₹73.13 Cr (up 44% YoY), EBITDA of ₹12.72 Cr at a 17.39% margin, and PAT of ₹9.03 Cr (up 25% YoY). Export revenue surged 164% to ₹6 Cr, with the veterinary segment contributing 55% of revenue and human healthcare 45%. Management set an FY2030 revenue target of ₹200 Cr, guided FY27 growth of ~40% CAGR, and expects EBITDA margins to recover to 20–22% over the next 2–3 years from the current dip caused by sales team expansion. The company is zero-debt, has acquired ₹2.5 Cr of land near Ahmedabad for a new ₹12–15 Cr manufacturing facility (mostly funded from internal accruals), and is targeting state government, CSD, CGHS, and KPKB procurement schemes for volume growth.
Positive for shareholders: strong topline growth, zero-debt status, and a clear multi-year scaling roadmap. However, near-term margins are compressed by expansion costs, working capital cycle remains stretched at 234 days, and a preference share issue has already diluted equity by 40%, which investors may weigh against the ambitious FY2030 targets.